FOXC2 and neoplasm: These results are consistent with those obtained when the pooled relative risk was calculated for stage T3-T4 tumor samples versus stage T1-T2 tumor samples (PRR = 1.367, 95%CI = 1.103–1.695, p = 0.004) Thus, the results from our meta-analysis indicate that FOXC2 is 36.7% more likely to be expressed in stage T3-T4 tumors than in stage T1-T2 tumors (Table 2).